Table 2.
Comparisons between intervention versus control groups at pretest versus posttest.
| Intervention group | Control group | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Pretest | Posttest | Change | N | Pretest | Posttest | Change | N | P-value | |
| Mobility | |||||||||
| AMAT total1 (0–45) | 29.3 (6.8) | 29.9 (6.6) | 0.6 | 24 | 28.9 (6.7) | 29.0 (7.7) | 0.2 | 26 | 0.60 |
| AMAT functional1 (0–21) | 14.6 (4.0) | 15.3 (3.7) | 0.6 | 24 | 15.4 (3.4) | 15.1 (4.0) | −0.3 | 26 | 0.08 |
| AMAT endurance1 (0–24) | 14.7 (3.3) | 14.7 (3.6) | 0.0 | 24 | 13.5 (3.7) | 13.9 (4.0) | 0.4 | 26 | 0.29 |
| STS scale1 (% of knee height) | 103.3 (22) | 103.8 (24.3) | 0.4 | 24 | 102.3 (22.5) | 103.1 (23.5) | 0.8 | 26 | 0.86 |
| TUG (sec)1 | 10.8 (6.5) | 11.0 (6.5) | 0.2 | 24 | 9.5 (3.2) | 9.6 (3.7) | 0.1 | 26 | 0.93 |
| Actical total activity (average count per day)1, 2 | 53,949 (42,610) | 61,797 (48,383) | 7848 | 20 | 69,326 (51,539) | 70,498 (50,508) | 1171 | 23 | 0.19 |
| Molecular | |||||||||
| CK (U/L) | 1038 (616) | 1098 (671) | 61 | 24 | 1232 (1174) | 1153 (1183) | −79 | 26 | 0.06 |
| IGF-1 (ng/mL) | 137.8 (51.0) | 137.6 (54.6) | −0.3 | 24 | 155.3 (39.5) | 154.0 (41.3) | −1.3 | 26 | 0.88 |
| Testosterone, total (ng/dL) | 385.2 (109.6) | 396.2 (124.3) | 10.9 | 24 | 382.4 (153.9) | 406.4 (172.5) | 24 | 26 | 0.57 |
| Overall health | |||||||||
| BDI (0–21) | 8.4 (5.6) | 8.8 (5.7) | 0.3 | 24 | 10.6 (8.1) | 8.7 (6.7) | −1.9 | 26 | 0.07 |
| SF36v2 PCS1 | 32.9 (7.0) | 33.0 (7.3) | 0.4 | 23 | 33.1 (6.9) | 34.1 (7.4) | 1.0 | 26 | 0.74 |
| SF36v2 MCS1 | 54.6 (9.4) | 53.3 (10.0) | −1.3 | 23 | 53.1 (12.0) | 54.4 (10.3) | 1.3 | 26 | 0.26 |
| SF36v2 VT | 45.4 (20.6) | 46.7 (20.5) | 1.4 | 23 | 44.5 (20.3) | 48.6 (19.5) | 4.1 | 26 | 0.48 |
| Strength | |||||||||
| QMA total (scaled to BMI)1 | 9.26 (2.51) | 9.08 (2.59) | −0.18 | 24 | 8.77 (3.65) | 8.93 (3.87) | 0.16 | 24 | 0.08 |
| QMA upper extremity | 2.71 (1.17) | 2.74 (1.15) | 0.03 | 24 | 2.62 (1.14) | 2.62 (1.19) | 0.00 | 25 | 0.75 |
| QMA lower extremity | 6.43 (2.42) | 6.54 (2.68) | 0.11 | 24 | 6.13 (1.98) | 5.98 (1.96) | −0.14 | 25 | 0.13 |
| Balance | |||||||||
| mCTSIB composite (COG sway velocity in deg/sec)1 | 1.5 (0.8) | 1.5 (0.7) | −0.2 | 20 | 1.3 (0.5) | 1.3 (0.5) | 0.0 | 23 | 0.73 |
| MCT composite (latency in msec) | 154.0 (15.2) | 154.3 (15.5) | 0.3 | 21 | 146.4 (10.4) | 149.2 (10.9) | 2.8 | 22 | 0.23 |
STS scale utilized seven levels from 80% to 140% of knee height, which was measured from tibial crest to the floor. The SF36v2 is reported as a norm-based number (0–100 with 50 as the mean) calculated with Quality Metric software (Lincoln, RI). Data are given as mean (SD). AMAT, Adult Myopathy Assessment Tool; CK, creatine kinase; IGF-1, insulin-like growth factor 1; BDI, Beck Depression Inventory; SF36v2, short form quality of life survey; PCS, physical component summary; MCS, mental component summary; VT, vitality component; STS, progressive height sit-to-stand test; TUG, time up and go test; QMA, quantitative muscle assessment; BMI, body mass index; COG, center of gravity; mCTSIB, modified clinical test of sensory interaction on balance; MCT, motor control test.
Classification (low or high function) is a significant covariate.
Age is a significant covariate.